Mary Madison, RN, RAC-CT, CDP
Clinical Consultant – Briggs Healthcare
The last weekend of February 2020 saw a much welcome approval of a 3rd vaccine to protect Americans from the serious outcomes due to COVID-19.
CDC Director Rochelle Walensky issued a media statement on Sunday, February 28, 2021 announcing the signing of the ACIP (Advisory Committee on Immunization Practice) recommendation on the safety and effectiveness of the Janssen Biotech, Inc. COVID-19 vaccine for use in people age 18 and older. (Janssen is the vaccine arm of Johnson and Johnson.)
The previous day, Saturday, February 27, 2021 was the day the FDA issued the Emergency Use Authorization (EUA) for the Janssen COVID-19 vaccine. The 9-page authorization letter contains product and dosing information, conditions of authorization, vaccination providers, emergency response stakeholders, etc.
This is the 1st vaccine authorized for emergency use in the United States that is one single dose (Pfizer-BioNTech and Moderna are 2-dose vaccines). It is the 3rd vaccine to be authorized for use in the U.S.
The 23-page Fact Sheet for Healthcare Providers Administering Vaccineis also available on the Janssen/Johnson & Johnson COVID-19 landing page. On the landing page, you’ll see these options:
Tuesday, March 2, 2021, the CDC’s COCA (Clinician Outreach and Communicating Activity) is hosting a 1-hour webinar entitled What Clinicians Need to Know About Johnson & Johnson’s Janssen COVID-19 Vaccine.
This COCA Call will give clinicians an overview of the J&J Janssen COVID-19 vaccine. Clinicians will learn about vaccine characteristics and administration, vaccinating special populations, and contraindications. They will also get answers to a number of clinical questions CDC has received about this new vaccine.
At the conclusion of the session, the participant will be able to accomplish the following—
- Cite background information on the topic covered during the presentation.
- Discuss CDC’s role in the topic covered during the presentation.
- Describe the topic’s implications for clinicians.
- Discuss concerns and/or issues related to preparedness for and/or response to urgent public health threats.
Promote health improvement, wellness, and disease prevention in cooperation with patients, communities, at-risk populations, and other members of an interprofessional team of healthcare providers.
If you are unable to attend the live COCA Call, the recording will be available for viewing on the COCA Call webpage few hours after the live event ends.
The slide set will be available on the day of the call under “Call Materials” on the COCA Call webpage.
Advanced registration is not required.
Date: Tuesday, March 2, 2021
Time: 2:00 PM – 3:00 PM ET
A few minutes before the webinar starts, please click on the Zoom link below to join:
US: +1 669 254 5252 or
+1 646 828 7666 or
+1 551 285 1373 or
+1 669 216 1590
Or iPhone one-tap:
Webinar ID: 160 374 8312
International numbers available: